Patient Demographics
| Variable . | Category or Value . | IFN 0-5 mo (n = 136) . | IFN ≥6 mo (n = 48) . | P Value . |
|---|---|---|---|---|
| No. of Patients (%) | ||||
| HLA compatibility | Match | 95 (69%) | 34 (70%) | .3 |
| A or B mismatch | 9 (7%) | 6 (13%) | ||
| DRB1 or DQB1 mismatch | 24 (18%) | 4 (9%) | ||
| Multiple mismatch* | 8 (6%) | 4 (8%) | ||
| Patient age (yr) | <20 | 10 (7%) | 4 (9%) | .7 |
| 20-35 | 60 (44%) | 19 (41%) | ||
| 36-50 | 62 (46%) | 22 (46%) | ||
| >50 | 4 (3%) | 3 (6%) | ||
| Gender match | (donor to patient) | .5 | ||
| M to M | 37 (27%) | 12 (25%) | ||
| M to F | 42 (31%) | 11 (23%) | ||
| F to M | 30 (22%) | 11 (23%) | ||
| F to F | 27 (22%) | 14 (29%) | ||
| Donor parity | F to M | 19 (14%) | 7 (15%) | .9 |
| Patient weight ≥10% above ideal | 75 (55%) | 17 (35%) | .02 | |
| Busulfan | 25 (19%) | 7 (15%) | .6 | |
| CMV prophylaxis-151 | 98 (72%) | 37 (77%) | .4 | |
| Fungal prophylaxis-151 | 69 (51%) | 31 (65%) | .1 | |
| CML duration (yr) | (diagnosis to transplant) | .001 | ||
| ≤1 | 60 (44%) | 6 (13%) | ||
| 1-3 | 54 (40%) | 23 (49%) | ||
| >3 | 22 (16%) | 19 (40%) | ||
| Transplant year | 1988-90 | 54 (40%) | 10 (21%) | .04 |
| 1991-92 | 41 (30%) | 22 (46%) | ||
| 1993-94 | 41 (30%) | 16 (33%) | ||
| g/dL | ||||
| Serum albumin | Median (range) | 3.8 (2.4, 4.6) | 3.3 (2.6, 4.5) | .03 |
| Percent score | ||||
| Kernofsky status | Median (range) | 100 (70, 100) | 90 (70, 100) | .007 |
| Years | ||||
| Donor age | Median (range) | 38 (20, 57) | 38 (23, 53) | .5 |
| No. of cells × 108/kg | ||||
| Marrow cell dose | Median (range) | 3.3 (0.65, 14.3) | 3.4 (1.7, 11.4) | .6 |
| Variable . | Category or Value . | IFN 0-5 mo (n = 136) . | IFN ≥6 mo (n = 48) . | P Value . |
|---|---|---|---|---|
| No. of Patients (%) | ||||
| HLA compatibility | Match | 95 (69%) | 34 (70%) | .3 |
| A or B mismatch | 9 (7%) | 6 (13%) | ||
| DRB1 or DQB1 mismatch | 24 (18%) | 4 (9%) | ||
| Multiple mismatch* | 8 (6%) | 4 (8%) | ||
| Patient age (yr) | <20 | 10 (7%) | 4 (9%) | .7 |
| 20-35 | 60 (44%) | 19 (41%) | ||
| 36-50 | 62 (46%) | 22 (46%) | ||
| >50 | 4 (3%) | 3 (6%) | ||
| Gender match | (donor to patient) | .5 | ||
| M to M | 37 (27%) | 12 (25%) | ||
| M to F | 42 (31%) | 11 (23%) | ||
| F to M | 30 (22%) | 11 (23%) | ||
| F to F | 27 (22%) | 14 (29%) | ||
| Donor parity | F to M | 19 (14%) | 7 (15%) | .9 |
| Patient weight ≥10% above ideal | 75 (55%) | 17 (35%) | .02 | |
| Busulfan | 25 (19%) | 7 (15%) | .6 | |
| CMV prophylaxis-151 | 98 (72%) | 37 (77%) | .4 | |
| Fungal prophylaxis-151 | 69 (51%) | 31 (65%) | .1 | |
| CML duration (yr) | (diagnosis to transplant) | .001 | ||
| ≤1 | 60 (44%) | 6 (13%) | ||
| 1-3 | 54 (40%) | 23 (49%) | ||
| >3 | 22 (16%) | 19 (40%) | ||
| Transplant year | 1988-90 | 54 (40%) | 10 (21%) | .04 |
| 1991-92 | 41 (30%) | 22 (46%) | ||
| 1993-94 | 41 (30%) | 16 (33%) | ||
| g/dL | ||||
| Serum albumin | Median (range) | 3.8 (2.4, 4.6) | 3.3 (2.6, 4.5) | .03 |
| Percent score | ||||
| Kernofsky status | Median (range) | 100 (70, 100) | 90 (70, 100) | .007 |
| Years | ||||
| Donor age | Median (range) | 38 (20, 57) | 38 (23, 53) | .5 |
| No. of cells × 108/kg | ||||
| Marrow cell dose | Median (range) | 3.3 (0.65, 14.3) | 3.4 (1.7, 11.4) | .6 |
*Multiple mismatch denotes donor and recipient incompatibility for one antigen at HLA-A or B plus one at DRB1 or DQB1 or one at DRB1 plus one at DQB1.
CMV and fungal prophylaxis are defined in the Patients and Methods.